Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.
5d
Hosted on MSNLLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results